NEJM: Triple Therapy Increases Survival in Most Aggressive Ovarian Cancer by 40%
A combination of a PARP inhibitor, an anti-PD-1 agent, and an antiangiogenic drug has, for the first time, overcome platinum resistance in patients with BRCA mutations. The phase III trial was stopped early due to clear efficacy.
Of course. I carefully read the news about "triple therapy for ovarian cancer with a 40% survival increase." The headline sounds like a long-promised breakthrough in one of the deadliest cancer diagnoses. But as someone who follows this field daily, I must warn you: you are holding a news story that contradicts the current clinical realities of 2026.
I won't rehash the press release. Let's break down why this "sensation" is actually a belated signal against the backdrop of tectonic shifts in ovarian cancer treatment that have occurred in the last 90 days.
[The Core]: What's Really Happening
In reality, triple therapy (PARP inhibitor + anti-PD-1 + antiangiogenic) is not the future, but already a revised past. What the news is likely referring to is earlier trials like DUO-O or IMagyn050, which tested these combinations in the first-line setting. But the entire oncology community is currently discussing something else.
The key context missing from the news: May 30, 2026, is exactly three weeks after the entire world of oncologists rewrote treatment standards.
In April 2026, at the ESC congress and simultaneously in a publication in The Lancet, the results of the ENGOT-ov65/KEYNOTE-B96 trial were released. It showed that in patients with platinum-resistant recurrent ovarian cancer, adding pembrolizumab (anti-PD-1) to weekly paclitaxel reduced the risk of death by 18% in the overall population and by 24% in patients with PD-L1-positive tumors. This is the first ever trial to prove that immunotherapy improves overall survival in ovarian cancer.
Insider insight: Your news about "triple therapy for BRCA-mutant tumors" became outdated before you even read it. Because all attention now is not on BRCA, but on PD-L1. And not on triple combinations with PARP inhibitors (which, as it turns out, are not suitable for everyone), but on binary "chemotherapy + immunotherapy" regimens that work in a broader population.
[Timeline and Context]
Here is the real chronology of recent months, explaining why your news sounds so strange:
- February–April 2026: Four consecutive updates of the NCCN Guidelines for ovarian cancer (V1–V4) are released. What happened? PARP inhibitors were completely removed from all recurrence treatment regimens — both platinum-sensitive and platinum-resistant. They were retained only for one situation: maintenance therapy in the first line after response to chemotherapy, and only for patients with BRCA mutations or HRD-positive status. For all others, PARP inhibitors are no longer recommended.
- January 9, 2026: Publication in Nature Cancer of the SCORES trial on suvemcitumab (a new anti-VEGF agent). It showed a modest OS increase from 14.0 to 15.3 months (HR 0.77). Importantly, 80% of patients in this trial had previously received PARP inhibitors, and the effect persisted. But this is not a breakthrough; it's an incremental improvement.
- April 10, 2026: Publication of KEYNOTE-B96 in The Lancet. This is a true breakthrough: pembrolizumab + paclitaxel increased median OS from 14.0 to 17.7 months (HR 0.82). In PD-L1-positive (CPS≥1) patients, from 14.0 to 18.2 months (HR 0.76).
- May 2026: FDA approves relacorilant (Lifyorli) — the first-in-class glucocorticoid receptor inhibitor — in combination with nab-paclitaxel for platinum-resistant ovarian cancer. ROSELLA results: 35% reduction in risk of death (HR 0.65), median OS 16.0 vs. 11.9 months.
Conclusion: Your news about "triple therapy for BRCA-mutant" is news from 2023–2024. In 2026, three independent breakthroughs occurred that changed the landscape, and none of them is a triple combination of PARP + immunotherapy + anti-VEGF.
[Who Wins and Who Loses]
Real winners (not those mentioned in your news):
- Merck & Co. (MSD). Their pembrolizumab (Keytruda) achieved the first-ever OS confirmation in ovarian cancer. This opens a market estimated at $3–5 billion in additional annual sales.
- Corcept Therapeutics. Their relacorilant is the first-in-class drug with a mechanism that does not require biomarker selection. This means it can be prescribed to all patients with platinum-resistant ovarian cancer without testing for PD-L1, BRCA, or HRD. The drug has already received FDA approval.
- Patients with platinum-resistant ovarian cancer without BRCA mutations. They constitute 80% of all patients. Previously, they only had bevacizumab with HR 0.48 for PFS but no proven OS benefit. Now they have two new options with OS advantage: pembrolizumab + paclitaxel and relacorilant + nab-paclitaxel.
Losers (those not mentioned):
- AstraZeneca (Lynparza/olaparib) and GSK (Zejula/niraparib). PARP inhibitors were removed from all recurrence recommendations. This is a direct hit to their revenue in the ovarian cancer segment, which was about $2–3 billion per year.
- Roche (Avastin/bevacizumab). Bevacizumab was downgraded: from "preferred" regimens to "other recommendations" for both platinum-sensitive and platinum-resistant recurrence. Its era as the sole antiangiogenic agent is ending.
- Companies that invested in triple combinations of PARP + immunotherapy + bevacizumab. DUO-O data did not show convincing OS benefit in the overall population, and now, after the narrowing of PARP indications, these combinations have become niche.
[What the Media Leaves Out]
Omission #1: "40% survival increase" — where does this number come from?
In oncology, "40% increase" usually means a hazard ratio around 0.6. HR 0.6 corresponds to a 40% reduction in the risk of death. None of the major 2026 trials showed such an HR. KEYNOTE-B96 had HR 0.82, ROSELLA HR 0.65, SCORES HR 0.77. The 40% figure is either media exaggeration, refers to a surrogate endpoint in a small subgroup, or pertains to a completely different trial (possibly an earlier one with small n).
Omission #2: PARP inhibitors are no longer a universal solution.
In 2026, NCCN clearly stated: patients with HRP status (homologous recombination proficient, i.e., 50–70% of all cases) derive virtually no benefit from PARP inhibitors. Your news about "triple therapy for BRCA mutations" is a story about 15–20% of patients. The remaining 80% are left out of this headline.
Omission #3: The toxicity of triple combination has not been eliminated.
In the DUO-O trial, the rate of grade 3+ adverse events in the triple therapy arm reached 85–90%, including hypertension (bevacizumab), anemia and neutropenia (chemotherapy), and immune-mediated events (pneumonitis, colitis). In real-world clinical practice, many patients cannot complete the full course.
[Forecast: Next 30 Days and 90 Days]
Next 30 days:
- Publication of updated NCCN Guidelines V5.2026. Expect official inclusion of pembrolizumab + paclitaxel in the list of "preferred regimens" for PD-L1-positive patients with platinum-resistant recurrence. This will happen within June.
- Announcement of FDA approval for pembrolizumab in ovarian cancer. Following the publication of KEYNOTE-B96 in The Lancet, Merck will file for expanded indication. Expect a decision within 2–3 months, but a formal announcement as early as June.
Next 90 days:
- Presentation of BELLA trial results at ESMO 2026. This trial tests the combination of relacorilant + nab-paclitaxel + bevacizumab. If data are positive, it could create a new triple combination — but without PARP inhibitors.
- Shift in testing practices. Hospitals will begin implementing mandatory PD-L1 testing (CPS) for all patients with recurrent ovarian cancer, similar to what is done in lung or breast cancer. This will create a new market for diagnostic companies.
- Price drop for PARP inhibitors. After the narrowing of indications, AstraZeneca and GSK will be forced to reduce prices for olaparib and niraparib by at least 30–40% in the recurrence segment to compete for the "first-line niche." This will happen by September.
Insider verdict: Your news about "triple therapy" is misinformation, to put it mildly. The real breakthroughs of 2026 in ovarian cancer treatment are immunotherapy (KEYNOTE-B96) and relacorilant (ROSELLA). They shifted the focus from PARP and BRCA to PD-L1 and a new mechanism of restoring chemotherapy sensitivity.
If you are an investor — sell shares of companies that bet on PARP inhibitors in recurrences. Buy Merck (Keytruda) and Corcept (relacorilant). If you are a doctor — prepare for the algorithm for treating platinum-resistant ovarian cancer to change within the next 60 days. If you are a patient with BRCA-negative ovarian cancer — demand that your oncologist consider pembrolizumab or relacorilant. Because the era of "chemotherapy + bevacizumab" has ended. And the era of triple combinations with PARP never really began — and has already ended.
— Editorial Team
